amyotrophic lateral sclerosis | Biomarker Commons

amyotrophic lateral sclerosis

Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments

The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have announced a partnership to explore using Denovo’s technology to identify potential responder groups for drugs being studied in ALS patients. This personalized medicine approach may accelerate drug development in ALS and other life-threatening disorders.


Premium Subscription Required for Access


Premium Subscription Required for Access


Premium Subscription Required for Access


Premium Subscription Required for Access


Premium Subscription Required for Access